The complaint, filed by the firm Glancy Prongay Wolke & Rotter LLP, centers on allegations that Erasca failed to disclose that its preclinical data for ERAS-0015 relied on improper comparisons to RevMed. According to the litigation, this practice put the company at significant risk of violating patent and trade secret protections. Plaintiffs argue that these omissions rendered the company's public statements about its operations and business outlook materially misleading.

Those looking to participate in the case or seeking clarification on their legal rights may contact attorney Charles Linehan in Los Angeles. While the court has set an August 10, 2026, deadline for those seeking to act as lead plaintiff, individual shareholders are not required to take immediate action to remain part of the class, as they may choose their own counsel or remain absent members of the suit.